Collaboration aimed at discovery of small molecule inhibitors in pain management therapy
Jubilant’s extensive experience in drug discovery and pre-clinical development to be utilised by Orion to address pain management needs
Noida, India, May 13, 2014- Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation (Orion), the largest pharmaceutical company in Finland, today announced a path breaking drug discovery collaboration to discover small molecule inhibitors in neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit large population of people with unmet needs in the pain management area.
As per the terms of agreement, Jubilant’s extensive experience in drug discovery and pre-clinical development will be utilised by Orion to address pain management needs of Central Nervous System (CNS). Jubilant will offer integrated drug discovery services across early discovery, synthetic and medicinal chemistry including scale up and pre-clinical services. The research for the project, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (India) and some parts at Jubilant Discovery Center, USA.
Dr. Subir Kumar Basak, President of Jubilant Biosys Ltd., said: “We are excited to partner with Orion to offer integrated drug discovery services. Over the past few years, we have been strengthening our therapeutic area focused discovery platform, and this partnership serves as a validation of our efforts. We are confident of offering successful results to Orion at various stages of research.”
Dr. Jukka Sallinen, Head of CNS Research of Orion Pharma R&D, said; “Jubilant Biosys is widely recognised for its expertise in offering integrated services in Drug Discovery and Development Solutions and for its prodigious capabilities in Pain and Inflammation. With established ability to develop successful drugs, we consider Jubilant as our ideal partner to take forward our strategic business plans with optimum time-to-market and accuracy.”
Jubilant will receive research funding from Orion for delivering Hit, Lead Generation and Optimization milestone, according to a pre-defined research plan. Under the royalty based alliance, Orion will provide royalty to Jubilant and will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights.
About Jubilant Biosys Ltd.:
Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd. which is headquartered in Noida, India. Jubilant Biosys provides integrated drug discovery solutions to the global pharmaceutical industry. Biosys has pioneered the risk shared collaborative discovery research model and demonstrated their capabilities over the years through multiple partnerships with global pharmaceuticals firms in the therapeutic areas of Oncology, Metabolic Disorders, Pain & Inflammation, CNS and others. Learn more about us at www.jubilantbiosys.com
About Jubilant Life Sciences:
Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Ointments, Creams and Liquids and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of over 6300 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info, visit www.jubl.com.
About Orion
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs. Orion’s net sales in 2012 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion’s A and B shares are listed on NASDAQ OMX Helsinki. For more info, visit www.orion.fi